ATE503023T1 - Diagnose und prognose von brustkrebspatientinnen - Google Patents

Diagnose und prognose von brustkrebspatientinnen

Info

Publication number
ATE503023T1
ATE503023T1 AT02746538T AT02746538T ATE503023T1 AT E503023 T1 ATE503023 T1 AT E503023T1 AT 02746538 T AT02746538 T AT 02746538T AT 02746538 T AT02746538 T AT 02746538T AT E503023 T1 ATE503023 T1 AT E503023T1
Authority
AT
Austria
Prior art keywords
breast cancer
relates
diagnosis
prognosis
whose expression
Prior art date
Application number
AT02746538T
Other languages
English (en)
Inventor
Hongyue Dai
Yudong He
Peter Linsley
Mao Mao
Christopher Roberts
T Veer Laura Van
De Vijver Marc Van
Rene Bernards
A Hart
Original Assignee
Rosetta Inpharmatics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Inpharmatics Llc filed Critical Rosetta Inpharmatics Llc
Application granted granted Critical
Publication of ATE503023T1 publication Critical patent/ATE503023T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
AT02746538T 2001-06-18 2002-06-14 Diagnose und prognose von brustkrebspatientinnen ATE503023T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29891801P 2001-06-18 2001-06-18
US38071002P 2002-05-14 2002-05-14
PCT/US2002/018947 WO2002103320A2 (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients

Publications (1)

Publication Number Publication Date
ATE503023T1 true ATE503023T1 (de) 2011-04-15

Family

ID=26970946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02746538T ATE503023T1 (de) 2001-06-18 2002-06-14 Diagnose und prognose von brustkrebspatientinnen

Country Status (11)

Country Link
US (5) US7514209B2 (de)
EP (1) EP1410011B1 (de)
JP (2) JP2005500832A (de)
AT (1) ATE503023T1 (de)
AU (1) AU2002316251A1 (de)
CA (1) CA2451074C (de)
CY (1) CY1111677T1 (de)
DE (1) DE60239535D1 (de)
DK (1) DK1410011T3 (de)
PT (1) PT1410011E (de)
WO (1) WO2002103320A2 (de)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US20040248170A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of hyperlipidemia related gene transcripts in blood
US20060134635A1 (en) * 2001-02-28 2006-06-22 Chondrogene Limited Method for the detection of coronary artery disease related gene transcripts in blood
US20040265868A1 (en) * 1999-01-06 2004-12-30 Chondrogene Limited Method for the detection of depression related gene transcripts in blood
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US20040248169A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of obesity related gene transcripts in blood
US20040241728A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of lung disease related gene transcripts in blood
US20030216558A1 (en) * 2000-12-22 2003-11-20 Morris David W. Novel compositions and methods for cancer
AUPR278301A0 (en) 2001-01-31 2001-02-22 Bionomics Limited A novel gene
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
DE60239535D1 (de) 2001-06-18 2011-05-05 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US20030104426A1 (en) * 2001-06-18 2003-06-05 Linsley Peter S. Signature genes in chronic myelogenous leukemia
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
ES2431929T3 (es) * 2001-09-18 2013-11-28 Genentech, Inc. Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
AU2002342053A1 (en) * 2001-10-11 2003-04-22 The Johns Hopkins University Pancreatic cancer diagnosis and therapies
US20040009495A1 (en) * 2001-12-07 2004-01-15 Whitehead Institute For Biomedical Research Methods and products related to drug screening using gene expression patterns
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
CA2477096A1 (en) * 2002-02-20 2003-08-28 Ncc Technology Ventures Pte Limited Materials and methods relating to cancer diagnosis
DK2258872T3 (da) * 2002-03-13 2013-11-18 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
EP1575509B1 (de) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
US20060134622A1 (en) * 2002-12-20 2006-06-22 Meena Augustus Amplified cancer target genes useful in diagnosis and thereapeutic screening
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP2007524362A (ja) * 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
US7892745B2 (en) * 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20060263813A1 (en) * 2005-05-11 2006-11-23 Expression Diagnostics, Inc. Methods of monitoring functional status of transplants using gene panels
WO2004109290A2 (en) * 2003-05-30 2004-12-16 Rosetta Inpharmatics Llc Methods for identifying modulators of kinesin activity
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
US20050100933A1 (en) * 2003-06-18 2005-05-12 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
EP3170906B1 (de) 2003-06-24 2018-08-22 Genomic Health, Inc. Vorhersage der wahrscheinlichkeit eines wiederauftretens von krebs
EP3330875B1 (de) 2003-07-10 2021-12-01 Genomic Health, Inc. Expressionsprofilalgorithmus und -test zur prognose des wiederauftretens von brustkrebs
US20050112622A1 (en) 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
EP1980629A3 (de) 2003-08-28 2008-12-17 Ipsogen Erkennung einer erbb2-Gen-Expressions-Signatur bei Brustkrebs
GB0320648D0 (en) * 2003-09-03 2003-10-01 Randox Lab Ltd Molecular marker
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
CA2539107A1 (en) * 2003-09-19 2005-03-31 Arcturus Bioscience, Inc. Predicting breast cancer treatment outcome
GB0323226D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer diagnosis
EP1892306A3 (de) * 2003-10-06 2008-06-11 Bayer HealthCare AG Verfahren und Kit zur Untersuchung von Krebs
CA2551267C (en) 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
ES2504242T3 (es) * 2004-02-20 2014-10-08 Janssen Diagnostics, Llc Pronóstico de cáncer de mama
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US8019552B2 (en) * 2004-03-05 2011-09-13 The Netherlands Cancer Institute Classification of breast cancer patients using a combination of clinical criteria and informative genesets
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005106044A1 (en) * 2004-04-23 2005-11-10 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
JP5690039B2 (ja) * 2004-06-04 2015-03-25 バイオセラノスティクス インコーポレイテッドＢｉｏｔｈｅｒａｎｏｓｔｉｃｓ，Ｉｎｃ． 腫瘍の同定
US20120258442A1 (en) * 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
CN101027412B (zh) 2004-07-23 2017-04-26 环太平洋生物技术有限公司 用于膀胱癌检测的尿标记物
AU2005267756A1 (en) * 2004-07-30 2006-02-09 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
EP1627923A1 (de) * 2004-08-18 2006-02-22 Het Nederlands Kanker Instituut Mittel und Methoden für den Nachweis und die Klassifizierung von foIllikulären Lymphomen
WO2006029184A2 (en) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
EP1805676A1 (de) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Verfahren und computerprogrammprodukte zur analyse und optimierung von marker-kandidaten für die krebsprognose
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
US8747867B2 (en) 2004-09-30 2014-06-10 Ifom Fondazione Instituto Firc Di Oncologia Molecolare Cancer markers
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CA2585561C (en) 2004-11-05 2018-07-17 Genomic Health, Inc. Esr1, pgr, bcl2 and scube2 group score as indicators of breast cancer prognosis and prediction of treatment response
CA2592993C (en) * 2004-12-13 2013-06-18 National University Corporation Okayama University Method for detecting methylation in genes and method for examining neoplasm through detecting methylation in genes
US20060183893A1 (en) * 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
EP1874471A4 (de) * 2005-03-16 2008-12-10 Sidney Kimmel Cancer Ct Verfahren und zusammensetzungen zur vorhersage des todes durch krebs und des überlebens von prostatakrebs unter verwendung von genexpressionssignaturen
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
WO2006101273A1 (ja) * 2005-03-25 2006-09-28 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2006132971A2 (en) 2005-06-03 2006-12-14 Aviaradx, Inc. Identification of tumors and tissues
EP1910958A2 (de) * 2005-06-08 2008-04-16 Mediqual System und verfahren zur dynamischen bestimmung einer krankheitsprognose
EP1946118A4 (de) * 2005-11-10 2009-01-21 Aurelium Biopharma Inc Gewebediagnose für brustkrebs
US8014957B2 (en) * 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP2363205A3 (de) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen Und Verfahren Zur Verwendung Bei Der Bildung Und Kontrolle Von Nanoreaktoren
NZ545243A (en) 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
US20090098538A1 (en) * 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
CA2648580A1 (en) * 2006-04-07 2008-05-02 Xdx, Inc. Steroid responsive nucleic acid expression and prediction of disease activity
US7789081B2 (en) * 2006-04-20 2010-09-07 Whirlpool Corporation Modular frame chassis for cooking range
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530168B1 (de) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
WO2008009028A2 (en) * 2006-07-14 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of determining the prognosis of an adenocarcinoma
EP2077912B1 (de) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
WO2008021431A2 (en) * 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
EP2090588A4 (de) 2006-10-23 2010-04-07 Neocodex S L In-vitro-verfahren zur prognose und/oder diagnose von überempfindlichkeit gegen estrogene oder substanzen mit estrogener wirkung
KR100862972B1 (ko) 2006-10-30 2008-10-13 한국과학기술연구원 휘발성 유기 화합물 검색용 바이오마커 및 이를 이용한유해성을 나타내는 휘발성 유기 화합물 검색 방법
US8148067B2 (en) * 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
CN101631454A (zh) 2006-12-08 2010-01-20 衣阿华州立大学研究基金公司 参与硝酸盐吸收和代谢的植物基因
AU2007334343A1 (en) * 2006-12-15 2008-06-26 Ordway Research Institute, Inc. Treatments of therapy-resistant diseases comprising drug combinations
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8030060B2 (en) * 2007-03-22 2011-10-04 West Virginia University Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
KR100886937B1 (ko) 2007-06-21 2009-03-09 주식회사 랩 지노믹스 유방암 및 난소암의 예측 또는 진단에 유용한 ｂｒｃａ1,ｂｒｃａ2 유전자 돌연변이
JP5303132B2 (ja) * 2007-09-20 2013-10-02 シスメックス株式会社 がん細胞の存否を判定する方法及び装置
EP2093567A1 (de) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1-mRNA-Expressionsebenen zur Vorhersage der Überlebensaussichten von mit neoadjuvanter Chemotherapie behandelten Brustkrebspatienten
US20110053804A1 (en) * 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP2159291A1 (de) 2008-09-01 2010-03-03 Agendia B.V. Mittel und Verfahren zur Bestimmung des Tumorzellenanteils in einer Probe
EP2202320A1 (de) 2008-12-24 2010-06-30 Agendia B.V. Verfahren und Mittel zur Typisierung einer Probe mit Kolorektalkrebszellen
US20100204973A1 (en) * 2009-01-15 2010-08-12 Nodality, Inc., A Delaware Corporation Methods For Diagnosis, Prognosis And Treatment
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2241634A1 (de) * 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnoseverfahren und Werkzeuge zur Vorhersage der Effizienz von gezielten Mitteln gegen IGF-1-Pfadaktivierung bei Krebs
CA2759079A1 (en) 2009-04-20 2010-10-28 Medical College Of Georgia Research Institute, Inc. Breast cancer susceptibility gene gt198 and uses thereof
US8637240B2 (en) * 2009-09-28 2014-01-28 Institute For Systems Biology Use of gene expression signatures to determine cancer grade
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
AU2010309988A1 (en) * 2009-10-21 2012-06-14 Basf Plant Science Company Gmbh Method for generating biomarker reference patterns
US20130029926A1 (en) * 2009-11-05 2013-01-31 Myriad Genetics, Inc. Compositions and methods for determing cancer susceptibility
MX337650B (es) * 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
ES3027507T3 (en) * 2010-01-11 2025-06-16 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
US20120196768A1 (en) 2010-04-22 2012-08-02 Toray Industries, Inc. METHOD FOR PREPARING aRNA AND METHOD FOR ANALYSIS OF GENE EXPRESSION
JP5725274B2 (ja) 2010-04-22 2015-05-27 国立大学法人大阪大学 乳癌の予後の検査方法
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012061510A2 (en) * 2010-11-03 2012-05-10 Merck Sharp & Dohme Corp. Methods of predicting cancer cell response to therapeutic agents
WO2012070056A2 (en) * 2010-11-23 2012-05-31 Krisani Biosciences (P) Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
WO2012079059A2 (en) 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP3859011A1 (de) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Verfahren zur bildung gemischter tröpfchen
EP2675819B1 (de) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
US20120252689A1 (en) 2011-04-01 2012-10-04 Zhong Wu Gene expression signature for wnt/b-catenin signaling pathway and use thereof
US8748587B2 (en) 2011-06-02 2014-06-10 Novartis Ag Molecules and methods for modulating TMEM16A activities
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2723899B1 (de) * 2011-06-21 2020-11-18 Children's Hospital Medical Center Verfahren zur diagnose von eosinophiler ösophagitis
US9175351B2 (en) 2011-07-13 2015-11-03 Agendia N.V. Means and methods for molecular classification of breast cancer
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
CN104080924A (zh) * 2011-08-16 2014-10-01 昂科赛特公司 用于治疗和诊断乳腺癌的方法和组合物
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
WO2013155567A1 (en) * 2012-04-20 2013-10-24 Mat Malta Advanced Technologies Limited Sex determination genes
EP2844768B1 (de) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digitale analyse von analyten
US9045546B2 (en) 2012-05-31 2015-06-02 Novartis Ag Molecules and methods for modulating TMEM16A activities
US9758829B2 (en) 2012-06-22 2017-09-12 Htg Molecular Diagnostics, Inc. Molecular malignancy in melanocytic lesions
EP2894477A4 (de) * 2012-09-05 2016-07-20 Wako Pure Chem Ind Ltd Verfahren zum nachweis von brustkrebs
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
CA2903878C (en) 2013-05-30 2020-10-27 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
EP3014505A4 (de) * 2013-06-28 2017-03-08 Nantomics, LLC Signalweganalyse zur identifizierung von diagnostischen tests
TW201546640A (zh) 2013-09-16 2015-12-16 Biodesix Inc 使用微分類器及規則化之組合的分類器產生方法與其用途
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
WO2015080585A1 (en) 2013-11-28 2015-06-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Methods for molecular classification of brca-like breast and/or ovarian cancer
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10370719B2 (en) * 2014-11-12 2019-08-06 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
US10980519B2 (en) 2015-07-14 2021-04-20 Duke University Systems and methods for extracting prognostic image features
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3374526A4 (de) 2015-11-13 2019-09-11 Biotheranostics, Inc. Integration von tumorcharakteristika mit einem brustkrebsindex
US10821094B2 (en) 2016-01-13 2020-11-03 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US10934590B2 (en) 2016-05-24 2021-03-02 Wisconsin Alumni Research Foundation Biomarkers for breast cancer and methods of use thereof
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
WO2019204580A1 (en) 2018-04-20 2019-10-24 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
EP3730941A1 (de) * 2019-04-23 2020-10-28 Institut Jean Paoli & Irène Calmettes Verfahren zur bestimmung des molekularen referenztumoraggressivitätsgradienten für ein duktales adenokarzinom des pankreas
WO2021221500A1 (en) 2020-04-27 2021-11-04 Agendia N.V. Treatment of her2 negative, mammaprint high risk 2 breast cancer.
US20220042106A1 (en) 2020-08-06 2022-02-10 Agendia NV Systems and methods of using cell-free nucleic acids to tailor cancer treatment
WO2022029488A1 (en) 2020-08-06 2022-02-10 Agenda Nv Systems and methods of assessing breast cancer
CN112927795B (zh) * 2021-02-23 2022-09-23 山东大学 基于bagging算法的乳腺癌预测系统
EP4526470A1 (de) 2022-05-19 2025-03-26 Agendia N.V. Vorhersage der reaktion auf eine immuntherapie bei brustkrebspatienten
US20260110035A1 (en) 2022-05-19 2026-04-23 Agendia N.V. Dna repair signature and prediction of response following cancer therapy
EP4621073A1 (de) 2024-03-22 2025-09-24 Istituto Europeo di Oncologia S.r.l. Verfahren zur prognose von brustkrebs

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US6342491B1 (en) 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US5677125A (en) 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer
WO1995019369A1 (en) 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
ATE270712T1 (de) 1995-03-17 2004-07-15 Wayne John Cancer Inst Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests
WO1997020931A1 (en) * 1995-12-08 1997-06-12 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method and compositions for monitoring dna binding molecules in living cells
AU724107B2 (en) 1997-01-31 2000-09-14 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin E
US6028189A (en) 1997-03-20 2000-02-22 University Of Washington Solvent for oligonucleotide synthesis and methods of use
NO972006D0 (no) * 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
US6432707B1 (en) 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6107034A (en) 1998-03-09 2000-08-22 The Board Of Trustees Of The Leland Stanford Junior University GATA-3 expression in human breast carcinoma
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6203987B1 (en) 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US7648826B1 (en) * 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US7013221B1 (en) 1999-07-16 2006-03-14 Rosetta Inpharmatics Llc Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
JP2003505038A (ja) 1999-07-16 2003-02-12 ロゼッタ・インファーマティクス・インコーポレーテッド オリゴヌクレオチドのハイブリダイゼーション特異性及び感受性を決定する方法
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
AU2596901A (en) 1999-12-21 2001-07-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001229340A1 (en) 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7118853B2 (en) 2000-07-26 2006-10-10 Applied Genomics, Inc. Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US20030215805A1 (en) 2001-04-20 2003-11-20 Millennium Pharmaceutical, Inc. Novel genes, compositions, kits, and methods for identification, assessment prevention, and therapy of breast cancer
DE60239535D1 (de) 2001-06-18 2011-05-05 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
EP3330875B1 (de) 2003-07-10 2021-12-01 Genomic Health, Inc. Expressionsprofilalgorithmus und -test zur prognose des wiederauftretens von brustkrebs
US8019552B2 (en) 2004-03-05 2011-09-13 The Netherlands Cancer Institute Classification of breast cancer patients using a combination of clinical criteria and informative genesets
AU2005267756A1 (en) 2004-07-30 2006-02-09 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
EP1848825A2 (de) 2005-02-04 2007-10-31 Rosetta Inpharmatics LLC. Verfahren zur vorhersage der ansprechbarkeit auf chemotherapie bei brustkrebspatienten

Also Published As

Publication number Publication date
US20110301048A1 (en) 2011-12-08
PT1410011E (pt) 2011-07-25
AU2002316251A1 (en) 2003-01-02
US7863001B2 (en) 2011-01-04
DE60239535D1 (de) 2011-05-05
US20090157326A1 (en) 2009-06-18
EP1410011B1 (de) 2011-03-23
CA2451074C (en) 2014-02-11
JP5237076B2 (ja) 2013-07-17
EP1410011A4 (de) 2007-08-01
US7514209B2 (en) 2009-04-07
JP2009131262A (ja) 2009-06-18
WO2002103320A3 (en) 2003-07-31
DK1410011T3 (da) 2011-07-18
JP2005500832A (ja) 2005-01-13
CA2451074A1 (en) 2002-12-27
CY1111677T1 (el) 2015-10-07
US9909185B2 (en) 2018-03-06
US20030224374A1 (en) 2003-12-04
WO2002103320A2 (en) 2002-12-27
EP1410011A2 (de) 2004-04-21
US20180305768A1 (en) 2018-10-25
US20130116145A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
DE60239535D1 (de) Diagnose und prognose von brustkrebspatientinnen
WO2004065545A3 (en) Diagnosis and prognosis of breast cancer patients
Takeshima et al. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk
WO2006015312A3 (en) Prognosis of breast cancer patients
Clarke et al. Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer
Massagué Sorting out breast-cancer gene signatures
Ludwig et al. Biomarkers in cancer staging, prognosis and treatment selection
Schlomm et al. Clinical significance of p53 alterations in surgically treated prostate cancers
Kim et al. Epigenetic markers as promising prognosticators for bladder cancer
Andreasen et al. The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA
Mehta et al. Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery
Geltzeiler et al. Staging HPV-related oropharyngeal cancer: validation of AJCC-8 in a surgical cohort
Skálová et al. Fusion‐positive salivary gland carcinomas
Sun et al. Hypermethylated PAX1 and ZNF582 genes in the tissue sample are associated with aggressive progression of oral squamous cell carcinoma
Lin et al. Klotho‐beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
Eyvazi et al. CpG islands methylation analysis of CDH11, EphA5, and HS3ST2 genes in gastric adenocarcinoma patients
Oczko-Wojciechowska et al. Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
Wang et al. The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer
Zhang et al. The signature of pharmaceutical sensitivity based on ctDNA mutation in eleven cancers
Tee et al. Genetic polymorphism of urokinase‐type plasminogen activator is interacting with plasminogen activator inhibitor‐1 to raise risk of cervical neoplasia
Wang et al. Screening of breast cancer methylation biomarkers based on the TCGA database
Wilkinson et al. WNT5A is a putative epi‐driver of prostate cancer metastasis to the bone
Aldakheel et al. Analysing DNA methylation and transcriptomic signatures to predict prostate cancer recurrence risk
Halachmi et al. Bladder cancer-genetic overview
Vastrad et al. A comprehensive transcriptome based meta-analysis to unveil the aggression nexus of oral squamous cell carcinoma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1410011

Country of ref document: EP